CI

Business Context and Reporting Period

Company: The Cigna Group
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Key Business Event: On March 19, 2025, the Company completed the divestiture of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, and related businesses to Health Care Service Corporation ("HCSC") for a total purchase price of $4.9 billion. This transaction significantly impacts year-over-year comparisons for the Cigna Healthcare segment.

Key Financial Metrics

Note: Q3 2024 debt and cash figures are not explicitly provided in the summary table but can be inferred from balance sheet trends; Q3 2025 debt includes $3.1B short-term and $30.9B long-term.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 10% in Q3 and 12% in the first nine months of 2025. This was driven by a 16% increase in Pharmacy revenues (Evernorth) and a 13% increase in Fees and other revenues. Conversely, Premiums decreased 21% in Q3 and 10% in 9M, primarily due to the HCSC divestiture.
• Profitability Surge: Shareholders' net income increased 153% in Q3 and 135% in 9M. The primary driver was the absence of a $2.7 billion impairment charge on VillageMD equity securities recorded in 2024. Net investment gains improved from a loss of $921 million in Q3 2024 to a gain of $26 million in Q3 2025.
• Segment Performance:
  • Evernorth Health Services: Adjusted revenues grew 15% (Q3) and 16% (9M) due to higher prescription drug utilization and customer growth.
  • Cigna Healthcare: Adjusted revenues declined 18% (Q3) and 9% (9M) due to the HCSC transaction. Pre-tax adjusted income decreased 12% (Q3) and 8% (9M), with the Medical Care Ratio (MCR) increasing to 84.8% in Q3.
• Divestiture Proceeds: The Company received approximately $4.2 billion in cash proceeds from the HCSC transaction at closing, with an additional $0.6 billion expected in Q4 2025.

Guidance, Outlook, and Risks

• Strategic Optimization Program: The Company incurred $222 million (Q3) and $566 million (9M) in pre-tax costs related to an enterprise-wide initiative to improve efficiency, including severance and asset impairments. Substantially all accrued liabilities are expected to be paid by the end of 2026.
• Capital Allocation: The Company repurchased 8.2 million shares for approximately $2.6 billion in the first nine months of 2025. A quarterly dividend of $1.51 per share was declared for Q4 2025.
• Debt Management: In September 2025, the Company issued $4.5 billion in new senior notes to repay a $2.0 billion term loan used for an investment in Shields Health Solutions and for general corporate purposes. The debt-to-capitalization ratio stood at 44.9% as of September 30, 2025.
• Risks: Key risks include the impact of the rebate-free pharmacy model transition, medical cost trends exceeding assumptions, regulatory changes, and credit risk associated with reinsurers and commercial mortgage loans. The Company noted that office sector fundamentals remain weak but are stabilizing for higher-quality assets.

Investor Verification Checklist

• HCSC Transaction Impact: Verify the final purchase price adjustments and the timing of the remaining $0.6 billion proceeds expected in Q4 2025.
• Investment Portfolio Quality: Review the allowance for credit losses on debt securities ($118 million) and the unrealized depreciation position ($384 million) in the context of rising interest rates.
• Medical Cost Trends: Monitor the Medical Care Ratio (MCR) for Cigna Healthcare, which increased to 84.8% in Q3 2025, driven by stop loss reserves and individual plan performance.
• Strategic Optimization Costs: Track the execution of the $566 million (9M) cost-saving initiative and its impact on future SG&A expenses.
• Pharmacy Model Transition: Assess the financial impact of the transition to a rebate-free pharmacy benefits model announced for Evernorth Health Services.